Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Health Policy topic
No spam. Unsubscribe anytime.
House panel advances bill to restrict delivery and advertising of abortion‑inducing drugs, after intense debate and amendments
Summary
After hours of proponent and opponent testimony, the House State Affairs Committee adopted an amendment changing 'solicit' to 'advertise' and voted to give HB 12‑74 a due‑pass recommendation; supporters described enforcement tools and AG Jackley outlined Comstock Act and other enforcement mechanisms, while medical groups cautioned about chilling effects on miscarriage care.
The House State Affairs Committee voted to advance House Bill 12‑74, as amended, after extended testimony from law‑enforcement officials, pro‑life advocates and medical groups.
Representative John Hughes, the prime sponsor, said the revised amendment (12‑74C and later 12‑74D) refocuses the bill to prohibit "dispensing, distribution, sale, or advertising of certain articles or things for purposes of an unlawful abortion" and to provide criminal and civil enforcement tools. "This is more in the nature of proactive to keep the pills out, not letting them get here in the first place," Attorney General Marty Jackley told the committee and described two enforcement changes: removing the requirement that a defendant be a "pregnant female" as an element of the offense and invoking the Comstock Act (18 U.S.C. 1461) to enable federal mailing prosecutions in some cases.
Proponents included state and national pro‑life organizations and physicians who described cases of incomplete medical abortions and heavy bleeding after mail‑order pills.
Opponents — including the South Dakota State Medical Association, the American College of Obstetricians and Gynecologists (state chapter) and the ACLU of South Dakota — argued the amendment's language (especially before the change from "solicit") risked criminalizing pregnant people who seek care, chilling legitimate medical uses of mifepristone and misoprostol (for miscarriage management and other conditions), and encouraging invasive investigations into pharmacy and mail records.
The wording was amended in committee: Representative Gosh moved to replace "solicit" with "advertise" (amendment 12‑74D), addressing a key concern raised by medical witnesses. After further debate, the committee moved a due‑pass on HB 12‑74 as amended; roll call recorded at the hearing showed the motion passed with 10 ayes, 2 noes and 1 excused.
The transcript records detailed committee questions about scope, potential unintended consequences for medical care, and enforcement mechanics. The bill now goes to the House floor with the committee's due‑pass recommendation.
